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As in any well-ordered society, individual
cells in complex multicellular organisms
must obey the laws and live within the
confines of their normal environment.
Malignant progression is the conse-
quence of cellular anarchy, where devel-
oping tumor cells acquire alterations that
allow them to flout the rules governing
where and when proliferation and sur-
vival can take place. A series of check-
points operate to ensure that order is
maintained, and an integral part of this
team is p53—an efficient hitman that can
take out cells attempting to proliferate
beyond their defined limits. Under some
circumstances, p53 achieves this end by
inducing cell death, thereby completely
eliminating the errant cell. But on other
occasions, p53 shows some leniency,
inducing a cell cycle arrest that might
potentially be reversible should the cell
be rehabilitated (Vousden and Lu, 2002).
Clearly, these are very different respons-
es, and the issue of why some cells die
while others arrest in response to p53
activation is of considerable interest.
Particularly provocative is the obser-
vation that activation of proteins that can
drive cell proliferation—like Myc—also
tilts the response to p53 activation
toward apoptosis. Deregulated prolifera-
tion is one of the linchpins underlying
malignant progression—a mission-criti-
cal event that is required for any cancer
to develop (Evan and Vousden, 2001).
The concomitant sensitization of cells
with proliferative abnormalities to death
means that successful cancer cells must
acquire additional alterations—like loss
of p53—to allow them to survive. The
assumption is that cancer cells are more
likely than normal cells to undergo apop-
tosis following repair of these lesions—
for example, following reactivation of
p53. Understanding what determines the
choice of response to p53, how deregu-
lated proliferative events also promote
apoptosis, and how these pathways are
derailed in tumors have therefore
become key questions in the field.
Two models—which are not mutually
exclusive—have emerged to explain the
choice of response to p53. The first sug-
gests that in the process of malignant
progression, cells are exposed to death
signals that cooperate with p53 to reach
an apoptotic threshold. In this model, the
activity of p53 remains the same regard-
less of the outcome, which is determined
by the presence or absence of additional
signals. In the second model, the
response is determined by changes in
the function of p53 itself—more specifi-
cally, the differential regulation of p53’s
DNA binding and transcriptional activity.
Phosphorylation of p53 and the availabil-
ity of apoptotic cofactors have been
shown to be required for transcriptional
activation of some apoptotic target
genes, but dispensable for the induction
of genes mediating the cell cycle arrest
(Figures 1A and 1B).These studies raise
the possibility that the switch to an apo-
ptotic response may reflect expression
or activation of critical kinases or cofac-
tors required for p53 to induce apoptotic
target genes, and that cancer cells may
survive because these factors are lost or
mutated (Vousden and Lu, 2002).
Now Seoane et al. (2002) have
uncovered a new mechanism through
which Myc can switch the p53 response
to apoptosis—not by affecting whether
p53 can induce activators of apoptosis,
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Cells can respond to the activation of the tumor suppressor protein p53 by undergoing cell cycle arrest or apoptosis, and
Myc has now been shown to help switch the response to apoptosis by repressing the expression of p21CIP1, a cyclin-depen-
dent kinase inhibitor with antiapoptotic activity.
Figure 1. Simplified model of the mechanisms
that can help determine the choice of response
to p53
A: Activation of p53 in normal cells results in
selective ex pression of a group of p53 target
genes that mediate cell cycle arrest, but not the
apoptotic targets. The expression of p21CIP1the
principal mediator of cell cycle arrest
depends on the activity of both p53 and Miz-1.
B: In response to some oncogenic changes,
modification or coactivator binding to p53
(mod) allows for the activation of apoptotic tar-
gets, like PUMA. However, the expression of p53-
inducible genes like p21CIP1 can block imple-
mentation of the apoptotic response.
C: A further signal, such as deregulated Myc, is
required for the inhibition of p21CIP1 expression
by the Miz/Myc complex and induction of
apoptosis.
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but by blocking the expression of a p53-
induced inhibitor of cell death. The p53
target gene in question is the cyclin-
dependent kinase inhibitor p21CIP1, the
principal mediator of p53-induced cell
cycle arrest. Although the p21CIP1 promot-
er is highly responsive to p53, it is now
evident that another transcription factor,
Miz-1, also plays a critical role in regulat-
ing p21CIP expression (Herold et al., 2002;
Seoane et al., 2002; van de Wetering et
al., 2002) (Figure 1A). Like p53, Miz-1
can be activated in response to stress,
and both transcription factors are
required for the induction of p21CIP1
expression (Herold et al., 2002). Previous
studies had shown that the transactiva-
tion activity of Miz-1 could be inhibited by
interaction with Myc (Seoane et al., 2001;
Staller et al., 2001), and the interaction of
Myc with Miz-1 also results in repression
of p21CIP1 transcription, even in the pres-
ence of activated p53. This observation
therefore nicely explains how Myc
expression can overcome the p53-medi-
ated block to cell cycle progression. In
addition, the regulation of p21CIP1 activity
through this Myc/Miz interaction plays an
important role in regulating the switch
from proliferation to differentiation (van
de Wetering et al., 2002). However,
p21CIP1 has another less well-explored
activity, which is the ability to protect cells
from p53-induced death signals. So in
removing the block to cell cycle progres-
sion, Myc also deprives the cells of this
survival signal. Importantly, because the
effect of Myc on p21CIP1 expression is
mediated though Miz-1, it does not direct-
ly affect p53 function.This means that the
activation of expression of other p53 tar-
get genes that encode proapoptotic pro-
teins like PUMA and PIG3 remains unaf-
fected (Seoane et al., 2002), and sug-
gests that ultimately the death response
is engaged by virtue of the loss of the
protective effect of p21CIP1 (Figure 1C).
The model is simple and elegant, but also
an incomplete view of how Myc sensi-
tizes cells to death. Herold et al. show
that a mutant of Myc that selectively fails
to bind Miz cannot repress expression of
p21CIP1—as expected—but retains the
ability to sensitize cells to apoptosis
(Herold et al., 2002).This mutant remains
competent in binding Max and functions
as a transcriptional activator, supporting
the proposal that part of the Myc apoptot-
ic signal is dependent on activation of
gene expression.
A closer consideration of these new
clues as to how Myc can switch the p53
response to apoptosis reveals some inter-
esting twists to the current thoughts on
choice of response to p53. Under some
conditions, inhibition of p53-mediated
apoptosis reveals an underlying cell cycle
arrest, suggesting that the cell cycle
arrest response remains intact in cells
destined to die. The implication is that the
choice of response to p53 is either induc-
tion of cell cycle arrest or induction of both
cell cycle arrest and apoptosis, with death
taking precedence in the latter situation.
The notion that apoptosis is somehow an
additional step that is superimposed onto
cell cycle arrest fits well with the idea that
unmodified forms of p53 that may be
induced in relatively normal cells activate
expression of only cell cycle arrest tar-
gets, and that further posttranscriptional
modification or cofactors are required to
allow activation of apoptotic targets
(Figure 1A and 1B). The new studies now
reveal an extra layer of complexity by
showing that even when both cell cycle
arrest and apoptotic target genes are
induced by p53, the resultant response
may still be cell cycle arrest. Under these
conditions, apoptosis ensues only follow-
ing selective inhibition of p53 target genes
that encode a survival function, like
p21CIP1. In this case, apoptosis would not
be superimposed onto an underlying cell
cycle arrest, which would also be eliminat-
ed with the loss of p21CIP1 (Figure 1C).
So what does p21CIP1 do to protect
the cells from apoptosis? The answer is
not clear, although there seems to be
some specificity to inhibition of the
mitochrondrial apoptotic pathways, since
induction of cell death by TRAIL is not
affected by loss of p21CIP1 (Javelaud and
Besancon, 2002). Although it has been
suggested that enhanced apoptotic sen-
sitivity following loss of p21CIP1 results
from elevated p53 expression, and there-
fore an increase in p53-induced apoptot-
ic signaling (Javelaud and Besancon,
2002), Seoane et al. show that p21CIP1
expression can protect from apoptosis
without significantly altering p53 activity.
These authors showed that the presence
of p21CIP1 did not protect from apoptosis
by reducing p53-mediated accumulation
of apoptotic proteins like PUMA or PIG3
(Seoane et al., 2002), suggesting that
p21CIP1 can function to impede the apo-
ptotic pathways downstream of p53. One
intriguing suggestion is that this reflects
the ability of p21CIP1 to block the activa-
tion of E2F1, another transcription factor
with apoptotic functions.
These studies represent an exciting
step forward in our understanding of how
the choice of response to p53 is regulat-
ed, and also generate a host of new
questions. Can p53 induce the expres-
sion of other antiapoptotic proteins that
can play a similar role to p21CIP1 and con-
tribute to the regulation of response even
when p21CIP1 levels remain constant?
Can related cyclin-dependent kinase
inhibitors, like p27KIP1, function in the
same way? Does the choice of response
to p53 induced by other stress signals
also depend on downregulation of
p21CIP1? Does deregulated expression of
p21CIP1 play a more general role in pro-
tecting tumor cells from apoptosis?
Leading to the most practical question:
could regulation of the transcription fac-
tors that control p21CIP1 expression be
beneficial in tumor therapy? These issues
are unlikely to remain a Miz-tery for long.
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